BOADICEA Calculator
Estimate breast cancer risk using a BOADICEA-style educational model based on age, family history, ovarian cancer history, known gene status, breast density, and prior atypia. This page is designed for understanding risk patterns and screening conversations, not for making a medical diagnosis.
Risk Calculator
Enter the details below to generate an educational risk estimate and chart. This tool approximates the kind of inputs used in hereditary breast and ovarian cancer risk assessment.
Your Results
Expert Guide to the BOADICEA Calculator
The BOADICEA calculator is associated with one of the best-known hereditary cancer risk modeling approaches used in breast cancer genetics. BOADICEA stands for Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm. In practice, the model is designed to estimate the likelihood that a person carries a pathogenic variant in genes such as BRCA1 or BRCA2 and to estimate future cancer risk by combining family history with personal risk factors. Modern implementations are often accessed through specialized clinical tools rather than a basic public calculator, but the underlying logic remains the same: family structure, age, tumor history, and genetics all matter.
This page provides a BOADICEA-style educational calculator that helps users understand how hereditary and non-hereditary risk factors can move risk up or down. It does not replace clinical genetics software, but it can help you organize a useful discussion before talking with a healthcare professional. If your result appears elevated, that does not mean you will develop cancer. It means that your pattern of risk factors may justify more detailed assessment, more careful screening, or a referral for genetic counseling.
What the BOADICEA model is designed to do
Traditional breast cancer risk tools often focus on a limited set of variables, such as age, age at first period, age at first birth, biopsy history, or the number of close relatives with breast cancer. BOADICEA is broader. It was built to model hereditary susceptibility in a detailed way. That means it can use complex pedigrees, ages of cancer diagnosis across relatives, ovarian cancer history, known pathogenic variants, and in some settings additional lifestyle or imaging information.
In a clinical context, BOADICEA-type models may estimate several related outcomes:
- Probability of carrying a pathogenic variant in a major breast or ovarian cancer predisposition gene.
- Short-term breast cancer risk, such as a 5-year or 10-year estimate.
- Remaining lifetime risk to a target age, commonly age 80.
- Potential ovarian cancer risk in selected hereditary syndromes.
The educational calculator on this page focuses on breast cancer risk because that is the most common public use case for the term BOADICEA calculator. It uses the same decision logic categories that matter clinically: age, family history, ovarian cancer in the family, gene status, breast density, and biopsy findings such as atypia or LCIS.
Why family history matters so much
Family history is not simply about counting how many relatives had cancer. The relationship to you, the age at diagnosis, whether there are multiple affected generations, and whether ovarian cancer or male breast cancer is present can all change the interpretation. A first-degree relative with breast cancer usually carries more weight than a second-degree relative. Multiple relatives with early-onset disease raise concern further. A family history that includes ovarian cancer can be especially important because it can suggest hereditary breast and ovarian cancer syndromes, particularly when paired with breast cancer in the same family line.
Even so, it is important to remember that many people with breast cancer have no strong family history, and many people with concerning family history never develop cancer. Risk models are probabilistic. They help sort people into risk groups so screening and prevention can be tailored more appropriately.
Key risk factors used in this BOADICEA-style calculator
- Current age: Risk is age-dependent. A 10-year risk estimate is very different at age 30 than at age 60.
- First-degree relatives with breast cancer: Mother, sister, or daughter history is highly relevant.
- Second-degree relatives with breast cancer: Aunts and grandmothers can still signal inherited susceptibility.
- Family history of ovarian cancer: This is particularly meaningful in BRCA-related syndromes.
- Known pathogenic variant: Confirmed BRCA1, BRCA2, PALB2, CHEK2, or ATM variants can substantially shift risk.
- Breast density: Dense breasts are associated with higher breast cancer risk and can make mammography less sensitive.
- Prior biopsy showing atypia or LCIS: These findings are markers of increased future risk.
- Ancestry clues: Certain founder mutations are more common in some populations, including Ashkenazi Jewish ancestry.
How to interpret the results
Most users care about two numbers. The first is the 10-year risk, which gives a near-term perspective that can be useful for screening discussions. The second is the remaining lifetime risk to age 80, which helps place long-term prevention and genetics questions in context. In many breast programs, a lifetime risk threshold of 20 percent or greater has historically been used to identify people who may benefit from supplemental MRI screening, although actual recommendations depend on the clinical model used and the full patient context.
Your result should be interpreted as a directional estimate, not a final answer. Consider these broad categories:
- Average range: Similar to or slightly above background population risk.
- Increased range: A meaningful elevation that may justify more tailored screening or discussion of risk reduction.
- High range: Strong consideration for formal genetics review, MRI eligibility review, and individualized prevention planning.
| Risk comparison | Estimated lifetime risk | Interpretation |
|---|---|---|
| Average U.S. female breast cancer risk | About 13.1% | Represents population-level lifetime risk according to SEER data. |
| Often used threshold for high-risk screening discussions | 20% or higher | Many breast clinics consider this level when discussing annual MRI in addition to mammography. |
| Clearly elevated hereditary-pattern risk | 30% or higher | Often prompts genetics review, especially when family history or a known variant is present. |
Data note: The 13.1% population statistic is consistent with U.S. SEER lifetime breast cancer risk reporting. Screening thresholds vary by guideline and by model used.
Real-world hereditary risk comparisons
One reason BOADICEA-type models are so valuable is that they can combine pedigree information with gene-specific data. A person with a BRCA1 or BRCA2 pathogenic variant is not simply at average risk. The magnitude of risk can be several times higher than population risk, although the precise estimate depends on the variant, age, family history, and competing events. The table below gives high-level hereditary comparisons that illustrate why genetic information matters so much.
| Group | Lifetime breast cancer risk | Lifetime ovarian cancer risk |
|---|---|---|
| General female population in the U.S. | About 13.1% | About 1.1% |
| BRCA1 pathogenic variant carriers | Roughly 45% to 90% | Roughly 39% to 58% |
| BRCA2 pathogenic variant carriers | Roughly 45% to 70% | Roughly 10% to 30% |
Source context: Population estimates are from U.S. cancer surveillance summaries. BRCA-related ranges are consistent with MedlinePlus Genetics and National Cancer Institute educational summaries.
What this calculator can and cannot tell you
This educational calculator can help you understand whether your risk profile looks average, increased, or potentially high. It can also show how different factors interact. For example, a person with no known mutation but multiple first-degree relatives and dense breasts may still have a clinically meaningful risk estimate. On the other hand, someone with a confirmed BRCA1 variant can have elevated risk even if the visible family history looks small, particularly in smaller families or family structures with fewer female relatives.
However, this page cannot evaluate all the details used in formal hereditary cancer risk modeling. It does not reconstruct a multigenerational pedigree, account for relatives’ exact ages at diagnosis, incorporate bilateral breast cancer, or calculate gene carrier probabilities with the depth used in official clinical software. It also does not substitute for pathology review, imaging interpretation, or medical judgment.
When to seek formal genetic counseling
You should strongly consider formal assessment if any of the following apply:
- Breast cancer diagnosed at a young age in you or a close relative.
- Ovarian cancer anywhere in the close family.
- Multiple relatives with breast cancer on the same side of the family.
- Male breast cancer in the family.
- A known pathogenic variant in BRCA1, BRCA2, PALB2, CHEK2, ATM, TP53, PTEN, or another hereditary cancer gene.
- Ashkenazi Jewish ancestry plus breast, ovarian, pancreatic, or prostate cancer in the family.
- A lifetime risk result high enough to change screening eligibility.
Genetic counseling is not only about ordering a DNA test. It is about selecting the right test, understanding false reassurance, explaining incomplete family histories, and choosing appropriate follow-up if a variant of uncertain significance or a pathogenic variant is found.
How dense breasts affect risk and screening
Breast density is relevant for two reasons. First, denser breasts are associated with higher risk compared with fatty breasts. Second, dense tissue can make mammograms less sensitive, which means some cancers are harder to detect. BOADICEA-style frameworks increasingly recognize that adding imaging-derived risk factors can sharpen risk estimates. In practical terms, if your calculator result is near an MRI eligibility threshold, breast density may influence the screening conversation.
Using risk estimates to make decisions
A good risk estimate helps answer practical questions:
- Should screening start earlier than standard population recommendations?
- Should breast MRI be added to mammography?
- Would a genetics referral be appropriate?
- Should risk-reducing medication be discussed?
- Is there value in building a more accurate family pedigree and obtaining relatives’ ages at diagnosis?
Many people assume that a risk calculator is only relevant if there is a known BRCA mutation. That is not true. A major advantage of BOADICEA-type thinking is that it helps identify people whose family pattern is important even before genetic testing occurs. This can be crucial for prevention because the first step is often not a medication or surgery, but simply recognizing that a person belongs in a high-risk pathway rather than an average-risk screening pathway.
Authoritative sources for further reading
If you want to validate the background science or understand the official population and hereditary risk numbers, these government resources are excellent starting points:
- SEER Breast Cancer Stat Facts
- National Cancer Institute BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet
- MedlinePlus Genetics: BRCA1 and MedlinePlus Genetics: BRCA2
Bottom line
The BOADICEA calculator concept is powerful because it brings together family history, genetics, and personal risk features into a more complete view of inherited cancer susceptibility. For users and clinicians alike, the biggest benefit is not just a single percentage. It is improved decision-making. If your estimate is elevated, that may signal the need for more detailed pedigree analysis, genetic counseling, or enhanced screening. If your estimate is lower, it can still support a more informed and less anxiety-driven conversation about your actual level of risk.
Use the calculator above as a structured starting point. Then, if your history is complex or your result is concerning, move to a formal genetics or breast risk clinic where official risk models can be applied with the precision needed for real clinical decisions.